The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in
both men and women worldwide. This is in spite of widespread, effective measures of …

Activation-induced cell death (AICD) of T lymphocytes can be exploited by cancers to
escape immunological destruction. We demonstrated that tumor-specific cytotoxic T …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality
worldwide. Its complexity is influenced by various signal transduction networks that govern …

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest
number of deaths from malignant neoplasms in women and the third largest number in men …

Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …

Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to
sustained suppression of MAPK signaling and suppressed tumor growth in BRAF V600E …